R. Willemze Et Al. , "High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial," JOURNAL OF CLINICAL ONCOLOGY , vol.32, no.3, pp.219-230, 2014
Willemze, R. Et Al. 2014. High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial. JOURNAL OF CLINICAL ONCOLOGY , vol.32, no.3 , 219-230.
Willemze, R., Suciu, S., Meloni, G., Labar, B., Marie, J., Halkes, C. J. M., ... Muus, P.(2014). High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial. JOURNAL OF CLINICAL ONCOLOGY , vol.32, no.3, 219-230.
Willemze, Roelof Et Al. "High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial," JOURNAL OF CLINICAL ONCOLOGY , vol.32, no.3, 219-230, 2014
Willemze, Roelof Et Al. "High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial." JOURNAL OF CLINICAL ONCOLOGY , vol.32, no.3, pp.219-230, 2014
Willemze, R. Et Al. (2014) . "High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial." JOURNAL OF CLINICAL ONCOLOGY , vol.32, no.3, pp.219-230.
@article{article, author={Roelof Willemze Et Al. }, title={High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial}, journal={JOURNAL OF CLINICAL ONCOLOGY}, year=2014, pages={219-230} }